Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05668962 · ClinicalTrials.gov registry record · Phase 2
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
A Phase 2 study of Thyroid Cancer and Papillary Thyroid Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT05668962: Recruiting Phase 2 study of Thyroid Cancer and Papillary Thyroid Cancer, sponsored by Massachusetts General Hospital.
NCT05668962 is a Phase 2 study of Thyroid Cancer and Papillary Thyroid Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05668962, a Phase 2 study of Thyroid Cancer and Papillary Thyroid Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).
Primary Outcome
RECIST v1.1 or Nies criteria in adolescents without RECIST-measurable disease The primary endpoint is best overall response (ORR) (CR and PR) at 6 months. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).Complete Response (CR) Disappearance of all target lesions. Any pathological lymph nodes (whether target or non
Conditions Studied
Interventions
- DRUG Selpercatinib
- DRUG Sodium Iodine I-131
- DRUG rhTSH
Study Locations (6)
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 2 |
What NCT05668962 shows while recruiting
NCT05668962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (89% lower).
The record links to 6 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 3 interventions - of which Selpercatinib is the first listed.
NCT05668962 lists 6 locations in 6 states (District of Columbia, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05668962 about?
NCT05668962 is a clinical study titled "Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC". This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination wi...
What is the current status of trial NCT05668962?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-03-01. Estimated completion is 2026-01-01.
What conditions does trial NCT05668962 study?
This clinical trial studies the following conditions: Thyroid Cancer, Papillary Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Thyroid Carcinoma, Follicular Thyroid Cancer.
What interventions are being tested in trial NCT05668962?
The interventions under investigation include: Selpercatinib (DRUG), Sodium Iodine I-131 (DRUG), rhTSH (DRUG).
Who is sponsoring clinical trial NCT05668962?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05668962 being conducted?
This trial has 6 study locations across District of Columbia, Florida, Massachusetts, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05668962's enrollment target sits among peer trials
30 32nd of 46 higher than 13 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
-
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI